Medical News

Abiraterone Acetate on the World Well being Group's Important Medicines Record for the Therapy of Prostate Most cancers

Janssen Pharmaceutical Firms of Johnson & Johnson welcome the current announcement by the World Well being Group (WHO) to incorporate abiraterone acetate (ZYTIGA ®) within the Therapy of Castration-Resistant Metastatic Prostate Most cancers (mCRPC), within the Up to date Record of Important Medicines, revealed on July 9, 2019.1,2

The WHO Important Medicines Record is a key steerage doc that helps international locations prioritize important well being commodities which are really helpful to be broadly and inexpensive in all well being techniques. well being.

The inclusion of abiraterone acetate within the WHO checklist of important medicine underscores the important function that this therapy can play in enhancing the lives of sufferers with mCRPC and their households. "

Dr. Joaquín Casariego, Janssen-Cilag S.A

specialist in oncology of the Janssen Therapeutic Area, Europe, Center East and Africa

Joaquín Casariego continued, "I’m pleased with what we’re working onerous for to have an effect on survival and high quality of life by creating and offering modern medicines that depend on scientific proof of the very best high quality. "

Janssen's scientific information of prostate most cancers relies on information gained by the event of modern therapy choices for mCRPC. Abiraterone acetate is an oral androgen biosynthesis inhibitor, accepted for the therapy of prostate most cancers mCRPC and metastatic prostate most cancers, in Europe.Three,four

The addition of abiraterone acetate to the checklist of important medicine is a crucial step for Janssen Oncology, reflecting the unremitting efforts made in recent times to supply optimum therapy choices to sufferers with mCRPC. "

Biljana Naumovic, Vice President of Enterprise Technique for Oncology for Europe, Center East and Africa, Cilag GmbH Worldwide

Biljana Naumovic continues: "This WHO guideline additional emphasizes that our work is just not but completed. It’s important that prostate most cancers sufferers have entry to remedies that their clinicians deem useful and that we proceed to assist the prostate most cancers neighborhood in our frequent purpose of creating most cancers a manageable and probably a day-to-day illness. , curable. "

About Janssen Pharmaceutical Firms of Johnson & Johnson

At Janssen, we create a future the place illness is a factor of the previous. We’re Johnson & Johnson's pharmaceutical firms, working tirelessly to make this future a actuality for all sufferers by combating illness by science, enhancing entry by ingenuity and therapeutic the world. despair with coronary heart. We deal with the areas of medication the place we are able to make the largest distinction: cardiovascular and metabolism, immunology, infectious ailments and vaccines, neuroscience, oncology and pulmonary hypertension.

About abiraterone acetate (ZYTIGA®)

Predirone-associated abiraterone acetate / prednisolone is an mCRPC-approved therapy that inhibits the manufacturing of androgens (which promote the expansion of prostate most cancers) on the three main sources of most cancers. Prostate most cancers – the testes, the adrenal glands and the tumor itself.four,5, 6

Abiraterone acetate is an oral therapy, taken together with prednisone / prednisolone for the therapy of: four

Excessive-risk metastatic hormone-responsive prostate most cancers (mHSPC) newly identified in grownup males together with anti-androgenic remedy (ADT)
mCRPC in asymptomatic or mildly symptomatic grownup males after failure of ADD in whom chemotherapy is just not but clinically indicated
CPRCm in grownup males whose illness progressed underneath or after a docetaxel chemotherapy routine


1. World Well being Group. WHO is updating world tips on medicine and diagnostic exams to deal with well being issues, prioritize extremely efficient remedies and enhance entry at inexpensive costs. Obtainable at: -challenges-prioritize- very effective-therapeutic-and-improve-affordable-access. Final accessed in July 2019.

2. World Well being Group. Mannequin Record of Important Medicines of the World Well being Group. Obtainable at with/10665/325771/WHO-MVP-EMP-IAU-2019.06en.pdf?sequence=1&isAllowed=y. Final accessed in July 2019.

Three. Bedoya DJ and Mitsiades N (2012). Abiraterone acetate, a first-class CYP17 inhibitor, establishes a brand new paradigm for therapy of castration-resistant prostate most cancers. Skilled Rev. Anticancer Ther. 12 (1), 1-Three.

four. European Medicines Company. Zytiga Abstract of product traits. Obtainable on the following deal with: Final accessed in July 2019.

5. Hoy, SM. et al. Abiraterone acetate: overview of its use in sufferers handled with metastatic medicine proof against prostate most cancers. Medicine 2013; 73: 2077-2091.

6. Ritch, CR. Cookson, MS. Progress within the administration of castration-resistant prostate most cancers. BMJ. October 17, 2016; 355: 14405. D10: 10.1136 / bd / i4405.